• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

CMS hesitates to approvePET for cancer despite data

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 31 No 1
Volume 31
Issue 1

Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage.

Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage. A CMS advisory panel came to the conclusion that clinical data for nine conditionally approved cancer indications of FDGPET were too ambivalent to support the petition.

The NOPR team suggested that making decisions case by case would be counterproductive. They remain optimistic that CMS will look favorably at the latest findings before making a final coverage decision, which is scheduled for January.

Recent Videos
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.